Abstracts tagged "Comorbidity"

Abstract Number: 1609 • ACR Convergence 2022
Comorbidity Clusters in Ankylosing Spondylitis and Their Association with Disease Activity and Functional Impairment: Data from the PSOAS Cohort
Paras Karmacharya¹, Cynthia Crowson², Ryan Lennon³, Dilli Poudel⁴, John Davis³, Alexis Ogdie⁵, Jean Liew⁶, Michael Ward⁷, Mariko Ishimori⁸, Michael Weisman⁹, Matthew Brown¹⁰, Mohammad Rahbar¹¹, Mark Hwang¹², John Reveille¹³ and Lianne Gensler¹⁴, ¹Vanderbilt University, Nashville, TN, ²Mayo Clinic, Eyota, MN, ³Mayo Clinic, Rochester, MN, ⁴Indiana Regional Medical Center, Indiana, PA, ⁵Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁶Boston University, Boston, MA, ⁷National Institutes of Health, Rockville, MD, ⁸Cedars-Sinai Health System, Los Angeles, CA, ⁹Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹⁰Genomics England, London, United Kingdom, ¹¹University of Texas Health Science Center at Houston, Houston, TX, ¹²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ¹³University of Texas McGovern Medical School, Houston, TX, ¹⁴Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Comorbidities occur more frequently in patients with ankylosing spondylitis (AS) than in the general population and are associated with higher morbidity and mortality. Some…
Abstract Number: 2009 • ACR Convergence 2022
Long-term Outcome of a Treat-to-target Strategy in Elderly-onset Rheumatoid Arthritis with Chronic Lung Diseases
Manami Nomura¹, Takahiko Sugihara², Hiroyuki Baba¹, Tatsuro Ishizaki³, Tadashi Hosoya¹, Mari Kamiya¹, Takumi Matsumoto², Kanae Kubo⁴, Fumio Hirano⁵, Masayo Kojima⁶, Nobuyuki Miyasaka⁵, Shinsuke Yasuda⁵ and Masayoshi Harigai⁷, ¹Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ²Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ³Human Care Research Team, Tokyo Metropolitan Institute of Gerontology., Tokyo, Japan, ⁴Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ⁵Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ⁶Department of Frailty Research, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, Nagoya, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan
Background/Purpose: Elderly patients with rheumatoid arthritis (RA) tend to have a higher risk for drug-related adverse events (AEs) than younger patients, and the effectiveness and…
Abstract Number: 0315 • ACR Convergence 2022
The Impact of Comorbidities on the Efficacy of IL-6 Inhibitor Olokizumab Compared to Adalimumab
Evgeny Nasonov¹, Eugen Feist², Michael Luggen³, Sergey Yakushin⁴, Daria Bukhanova⁵, Alina Egorova⁶, Sergey Grishin⁶, Mikhail Samsonov⁵ and Josef Smolen⁷, ¹V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ²Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany, ³University Hospital/University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Ryazan State Medical University named after academician I.P. Pavlov, Ryazan, Russia, ⁵R-Pharm JSC, Moscow, Russia, ⁶R-Pharm, Moscow, Russia, ⁷Medical University of Vienna, Vienna, Austria
Background/Purpose: Comorbid conditions may affect efficacy of treatment in patients with rheumatoid arthritis (RA). The aim of this analysis was to evaluate the impact of…
Abstract Number: 1637 • ACR Convergence 2022
Association of Dermatomyositis with Cardiovascular Disease: A Case-Control Study in the All of Us Research Program
Jill Shah¹, Keya Shah², Daniel Mazori¹, Avrom Caplan¹, Emily Hejazi¹ and Alisa Femia¹, ¹Ronald O. Perelman Department of Dermatology, New York University Langone Health, New York, NY, ²Department of Medicine, NYU Langone Hospital - Long Island, Mineola, NY
Background/Purpose: Previous studies on the association of dermatomyositis (DM) with cardiovascular (CV) disease have used combined idiopathic inflammatory myositis cohorts, included only non-United States (US)…
Abstract Number: 2080 • ACR Convergence 2022
Epidemiology and Outcomes of Emergency Department Visits in Systemic Lupus Erythematosus: Data from National Emergency Database Sample
Rashmi Dhital¹, Monica Guma², Brian Pedersen¹, Ashbina Pokharel³ and Kenneth Kalunian⁴, ¹UC San Diego, San Diego, CA, ²UCSD, La Jolla, CA, ³William Beaumont Hospital, Royal Oak, MI, ⁴University of California San Diego, La Jolla, CA
Background/Purpose: Patients with autoimmune rheumatic diseases presenting to the emergency department (ED) often have multi-organ pathology. SLE patients may be particularly prone to ED visits…
Abstract Number: 0387 • ACR Convergence 2022
Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity
Marta Ibañez Martinez¹, Sonia Pastor Navarro², Olga Compán Fernández², Belén Miguel Ibáñez², Ana Isabel Turrión Nieves², Susana Gómez Castro¹, Olga Martínez González², Cristina Hidalgo Calleja², Esther Toledano Martinez³ and Carlos Montilla Morales², ¹Hospital Universitario Salamanca, Salamanca, Spain, ²Hospital Universitario de Salamanca, Salamanca, Spain, ³Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: To evaluate the quality of sleep in patients with psoriatic arthritis (PsA) and its relationship with/to clinical variables, activity, functionality, the impact of the…
Abstract Number: 1643 • ACR Convergence 2022
Use of Oral Analgesics and Risk of Comorbidities in Osteoarthritis: Findings from Primary Care Settings in the UK
Subhashisa Swain¹, Carol Coupland², Anne Kamps³, Jos Runhaar⁴, Andrea Dell ‘Isola⁵, Aleksandra Turkiewicz⁵, Danielle E Robinson¹, Victoria Y Strauss¹, Christian Mallen⁶, Chang-Fu Kuo⁷, Aliya Sarmanova⁸, Daniel Prieto Alhambra¹, Martin Englund⁵, Sita Bierma-Zeinstra³, Michael Doherty² and Weiya Zhang², ¹University of Oxford, Oxford, United Kingdom, ²University of Nottingham, Nottingham, United Kingdom, ³Erasmus University Medical Centre, Rotterdam, Netherlands, ⁴Erasmus Medical Center, Rotterdam, Netherlands, ⁵Lund University, Lund, Sweden, ⁶Keele University, Keele, United Kingdom, ⁷Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁸University of Bristol, Bristol, United Kingdom
Background/Purpose: People with osteoarthritis (OA) often have multiple other conditions (comorbidities).Role of different oral analgesics on the development of comorbidities in people with OA have…
Abstract Number: 2091 • ACR Convergence 2022
Burden and Incidence of Multimorbidity in Systemic Lupus Erythematosus in a Community Population-Based Cohort: The Lupus Midwest Network
Gabriel Figueroa Parra¹, Jose Meade Aguilar¹, Cynthia Crowson², Cassondra Hulshizer¹, Tina Gunderson¹, Alanna Chamberlain¹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: As the life expectancy of patients with systemic lupus erythematosus (SLE) improves, comorbidities have become more critical. Multimorbidity (MM2+) is defined as the coexistence…
Abstract Number: 0697 • ACR Convergence 2022
Are Fibromyalgia and Depression as Common as Any Primary Diagnosis in Routine Rheumatology Care, Albeit as Secondary Diagnoses, but Which May Confound Clinical Assessment?
Theodore Pincus¹, Kathryn Gibson², Juan Schmukler¹, Tengfei Li³ and Joel Block¹, ¹Rush University Medical Center, Chicago, IL, ²Liverpool Hospital, Sydney, Australia, ³Georgetown University, Washington, DC
Background/Purpose: Fibromyalgia (FM) and depression (DEP) are common comorbidities of all reported primary rheumatic diagnoses, easily recognized in many patients, but often underestimated, particularly in…
Abstract Number: 1645 • ACR Convergence 2022
Evaluating the Use of Genetic Risk Scores as Part of an Integrated Risk Tool for Predicting Coronary Artery Disease in Patients with Rheumatoid Arthritis
Mehreen Soomro¹, Michael Stadler¹, Sebastien Viatte¹, Alex Macgregor², Suzanne Verstappen¹, Anne Barton¹ and John Bowes¹, ¹The University of Manchester, Manchester, United Kingdom, ²The University of East Anglia, Norwich, United Kingdom
Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher prevalence of coronary artery disease (CAD) than the general population, which contributes to early mortality. However,…
Abstract Number: 0888 • ACR Convergence 2022
Cardiovascular and Thromboembolic Events in Rheumatoid Arthritis Patients Before and After Initiation of a First Advanced Therapy. Data from the University of Sherbrooke Registry of Advanced Therapies (USRAT)
Nathalie Carrier¹, Sophie Roux², Hugues Allard-Chamard² and Gilles Boire³, ¹Centre intégré universitaire de santé et services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, QC, Canada, ²Université de Sherbrooke and Centre intégré universitaire de santé et services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, QC, Canada, ³Universite de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Uncontrolled inflammation in rheumatoid arthritis (RA) patients increases the risk for incident Ischemic Heart Disease (IHD) and venous thromboembolic (TE) events. Reducing inflammation using…
Abstract Number: 1646 • ACR Convergence 2022
Major Adverse Cardiovascular Events and Mortality with Opioids versus NSAIDs Initiation in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Sofia Pedro² and Kaleb Michaud³, ¹University of Nebraska Medical Center, Bellevue, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Pain management is challenging in RA where ~60% of patients with well-controlled disease activity still experience bothersome pain. The opioid epidemic in the US…
Abstract Number: 0922 • ACR Convergence 2022
Alteration of the Cardiometabolic and Cardiovascular Proteome in Rheumatoid Arthritis. Modulation by Methotrexate and Tofacitinib
Nuria Barbarroja¹, Carlos Pérez-Sánchez¹, Laura Cuesta-Lopez¹, Miriam Ruiz-Ponce¹, Ivan Arias-de la Rosa¹, Antonio Gonzalez², Eva Perez Pampin³, Chamaida Plasencia-Rodriguez⁴, Ana Martinez-Feito⁴, Rafaela Ortega-Castro¹, Jerusalem Calvo-Gutierrez⁵, Alejandro Balsa⁶, Alejandro Escudero-Contreras¹, Eduardo Collantes¹ and Chary López-Pedrera⁷, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain, ³Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago, Cordoba, Spain, ⁴Rheumatology Department, La Paz University Hospital, Madrid, Spain, ⁵IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ⁶Hospital La Paz Institute for Health Research, Madrid, Spain, ⁷Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain
Background/Purpose: Patients with rheumatoid arthritis (RA) have a high risk of suffering cardiovascular disease. The analysis of the cardiovascular and cardiometabolic proteome in RA patients…
Abstract Number: 1767 • ACR Convergence 2022
Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study
Bernhard Hellmich¹, Konstantin Neukirch², Marco Lukas², Martin Wernitz², Dominik Beier³ and Dennis Häckl⁴, ¹Department of Internal Medicine, Rheumatology and Immunology, Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, ²GlaxoSmithKline GmbH & Co. KG, Munich, Germany, ³InGef - Institute for Applied Health Research Berlin GmbH, Berlin, Germany, ⁴WIG2 GmbH, Leipzig, Germany
Background/Purpose: EGPA and HES are rare multisystemic diseases associated with eosinophilia. Robust data on the epidemiology and treatment of HES and EGPA are scarce. The…
Abstract Number: 1034 • ACR Convergence 2022
Characterization of Non-radiographic Axial Spondyloarthritis Patients and the Burden of Disease in Routine Clinical Practice
Kathryn Starzyk, Pam Kumparatana and roger Meng, OM¹, Inc., Boston, MA
Background/Purpose: Axial spondyloarthritis [AxSpA and particularly non-radiographic (nr)AxSpA] has one of the longest diagnostic delays in rheumatology. Although improving, lack of radiographic evidence of disease…

« Previous Page
1
…
4
5
6
7
8
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].